Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Geranium oil is an essential oil primarily derived from the plant *Pelargonium graveolens*. It is a complex mixture of bioactive small molecules, with major constituents typically including citronellol, geraniol, and linalool. The oil is investigated for a variety of clinical applications, most notably the topical treatment of neuropathic pain and numbness, where it is thought to provide analgesic relief. It also exhibits significant anti-inflammatory, antioxidant, and antimicrobial properties. Research suggests it may inhibit the secretion of pro-inflammatory cytokines and reduce microglial activation, offering potential neuroprotective benefits in models of Parkinson's disease. Geranium oil is categorized by the FDA as Generally Recognized as Safe (GRAS) and is utilized in diverse delivery systems, including nanoemulsions, hydrogels, and niosomes, to improve its stability and therapeutic efficacy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on geranium oil.